City

Clinical trials near Richmond, United States

Active studies with a listed research site in Richmond, United States.

13active studies

7recruiting now

10countries represented

43largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 2

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

Obesity, OverweightCondition

Macupatide, EloralintideTreatment

Argentina, Australia42 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07215559See eligibility →

Recruiting nowPhase 3

A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight

Overweight, ObesityCondition

Cagrilintide, Placebo cagrilintideTreatment

Greece, Hungary36 locations

Novo Nordisk A/SSponsor

Updated 2026-09-04 · NCT07745504See eligibility →

Recruiting nowPhase 2

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

Obesity, OverweightCondition

ABBV-295, PlaceboTreatment

Puerto Rico, United States38 locations

AbbVieSponsor

Updated 2026-09-03 · NCT07752979See eligibility →

Recruiting nowPhase 2, Phase 3

Focusing on the Menopausal Transition to Improve Mid-Life Women's Health

Menopause, Menopause Hot FlashesCondition

Metformin, semaglutideTreatment

United States3 locations

University of Colorado, DenverSponsor

Updated 2026-07-21 · NCT06975111See eligibility →

Recruiting nowPhase 2

A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

ObesityCondition

NNC0662-0419, SemaglutideTreatment

Puerto Rico, United States25 locations

Novo Nordisk A/SSponsor

Updated 2026-07-10 · NCT07639021See eligibility →

Recruiting nowPhase 2

Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant

NAFLDCondition

Semaglutide Pen Injector, PlaceboTreatment

United States1 locations

University of VirginiaSponsor

Updated 2026-06-04 · NCT05424003See eligibility →

Recruiting nowNot applicable

Redefining BMI: The Body, Mind, and Inflammation Trial

Obesity, AdiposityCondition

Integrated Lifestyle Intervention (ILI), Monitoring with digital toolsTreatment

United States1 locations

Virginia Commonwealth UniversitySponsor

Updated 2026-05-06 · NCT06532747See eligibility →

Opening soonPhase 3

A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide

Overweight, ObesityCondition

Zenagamtide, SemaglutideTreatment

United States43 locations

Novo Nordisk A/SSponsor

Updated 2026-08-25 · NCT07668414See eligibility →

Opening soonPhase 3

AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight

Overweight, ObesityCondition

zenagamtide, PlaceboTreatment

United States37 locations

Novo Nordisk A/SSponsor

Updated 2026-08-25 · NCT07720271See eligibility →

Invitation onlyNot applicable

Bariatric Surgery Registry

Obesity, MorbidCondition

Intervention not listedTreatment

United States1 locations

Virginia Commonwealth UniversitySponsor

Updated 2025-11-24 · NCT01055054See eligibility →

Active, not recruitingNot applicable

NOURISH-T+: Promoting Healthy Eating and Exercise Behaviors

Obesity, Childhood, CancerCondition

NOURISH-T+, Brief NOURISH-T+Treatment

United States10 locations

University of South FloridaSponsor

Updated 2026-08-12 · NCT04656496See eligibility →

Active, not recruitingPhase 2

A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

Obesity, OverweightCondition

VRB-101, PlaceboTreatment

United States20 locations

Verdiva Bio Dev LimitedSponsor

Updated 2026-08-04 · NCT07553299See eligibility →

Active, not recruitingPhase 3

A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight

Obesity, OverweightCondition

RetatrutideTreatment

Argentina, Canada35 locations

Eli Lilly and CompanySponsor

Updated 2026-06-09 · NCT07357415See eligibility →

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.

Clinical trials near Richmond, United States

Current studies

Related cities